Ocugen is trading at $1.03, down 5.05%, with no clear company-specific catalyst identified for the decline.
- On September 30, Ocugen announced scientific-conference presentations, including a company overview and upcoming research presentations.
- The announcement did not report or explain the share-price decline.
- The provided market context shows the Nasdaq up, so it does not establish a broad-market explanation for Ocugen’s drop.